J&J eye disease gene therapy bota-vec fails Phase 3
Article Title: J&J eye disease gene therapy bota-vec fails Phase 3 Publication Date: May 5, 2025 In an unfortunate turn of events, Johnson & Johnson’s pioneering gene therapy for X-linked retinitis pigmentosa (XLRP)—a genetic disease causing vision loss—failed in a…